GlassScriptPhysician profile
Roshan Patel
NPI 1801392717
$557.05
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.53 · 2021: $13.81 · 2022: $89.68 · 2023: $279 · 2024: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $104.53 | 2020-2024 | Rybelsus, Ozempic |
| Amgen INC. | $84.85 | 2023-2024 | Repatha, Prolia, Evenity |
| Lilly USA, LLC | $77.04 | 2020-2024 | Mounjaro |
| Exact Sciences Corporation | $74.22 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $58.07 | 2020-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $52.50 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $30.67 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.99 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $23.19 | 2023 | Shingrix, Bexsero, Pediarix |
| Alfasigma USA, INC. | $13.81 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.18 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roshan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.